The UK and US have secured a key trade agreement that will keep no tariffs on UK pharmaceutical exports being sold in the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This move guarantees that tariffs on these crucial goods will stay at nothing for a period of the next three years.
This agreement follows earlier warnings to hike tariffs on branded drug products, with potential rates discussed reaching 100%.
"This agreement with the UK bolsters the worldwide climate for cutting-edge drugs and introduces long-overdue balance to American-British medicine commerce," a statement said.
Economic Importance
Pharmaceuticals are one of the UK's most significant goods shipped to the United States, which is easily the largest destination for leading British pharmaceutical firms.
Export figures reveal that in the one-year period to the end of the third quarter, the UK shipped pharmaceutical products valued at £11.1bn to the US. This figure represented 17.4% of British export trade in that timeframe.
"This guarantee protects employment, increases investment and paves the way for the UK to become a global hub for life sciences," a government official commented.
Key British Pledges
The agreement entails several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a target to double overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to prevent overspending will be capped at fifteen percent. Previously, rebates topped 20%.
Industry Background
This agreement comes amid a long-running row between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
This friction were intensified by claims that US patients were paying several times more for the same drugs than patients in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS had to invest a greater share on drugs, noting that its spending on drugs had decreased as a share of its total funding over the previous ten-year period.
